MedPath

Dihydroartemisinin

Generic Name
Dihydroartemisinin
Drug Type
Small Molecule
Chemical Formula
C15H24O5
CAS Number
71939-50-9
Unique Ingredient Identifier
6A9O50735X
Background

Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections . It was first authorized for market by the European Medicines Agency in October 2011 in combination with Piperaquine as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization .

Indication

For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg . Used in combination with Piperaquine.

Associated Conditions
Malaria caused by Plasmodium falciparum
Clinical Trials
Related News

IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding

Not Applicable
Recruiting
Conditions
Malaria Infection
Malaria Falciparum
Interventions
Other: Long-lasting Insecticidal Net
Combination Product: Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis
First Posted Date
2025-03-11
Last Posted Date
2025-03-12
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
36000
Registration Number
NCT06870344
Locations
🇺🇬

Mbarara University of Science and Technology (MUST), Mbarara, Uganda

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Phase 2
Recruiting
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Drug: Placebo
First Posted Date
2025-02-24
Last Posted Date
2025-04-20
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
150
Registration Number
NCT06842524
Locations
🇨🇳

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

🇨🇳

Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China

🇨🇳

Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

and more 1 locations

Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia

Phase 3
Active, not recruiting
Conditions
Plasmodium Falciparum
Malaria
Interventions
First Posted Date
2024-07-23
Last Posted Date
2025-05-06
Lead Sponsor
PATH
Target Recruit Count
10350
Registration Number
NCT06516042
Locations
🇪🇹

Delello Farm Sites, Gondar, Metema District, Ethiopia

Efficacy of Dihydroartemisinin for Treating PCOS

Phase 2
Completed
Conditions
Polycystic Ovary Syndrome
Interventions
First Posted Date
2024-05-16
Last Posted Date
2025-04-23
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
30
Registration Number
NCT06417099
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy

Phase 4
Recruiting
Conditions
Falciparum; Malaria
Interventions
First Posted Date
2024-04-04
Last Posted Date
2025-03-10
Lead Sponsor
Infectious Diseases Research Collaboration, Uganda
Target Recruit Count
120
Registration Number
NCT06347471
Locations
🇺🇬

Dr. Ambrosoli Memorial Hospital, Kalongo, Agago district, Uganda

🇺🇬

Patongo Health Facility IV, Patongo, Agago district, Uganda

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Phase 4
Recruiting
Conditions
Malaria,Falciparum
Anemia in Children
Interventions
Drug: Sulfadoxine-pyrimethamine-amodiaquine
First Posted Date
2023-10-16
Last Posted Date
2024-10-18
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
1000
Registration Number
NCT06083688
Locations
🇲🇼

Malaria Alert Centre, Blantyre, Malawi

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Phase 2
Completed
Conditions
Malaria, Vivax
Infections
Malaria,Falciparum
Uncomplicated Malaria
Malaria
Uncomplicated Plasmodium Falciparum
Interventions
Other: Momordica Charantia Extract
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Syamsudin Abdillah,Ph.D, Pharm D
Target Recruit Count
50
Registration Number
NCT06036030
Locations
🇮🇩

Manokwari Regional General Hospital, Manokwari, West Papua, Indonesia

Comparing Chemoprevention Drugs for School-based Malaria Control

Phase 4
Completed
Conditions
Anemia in Children
Malaria,Falciparum
Interventions
First Posted Date
2023-08-07
Last Posted Date
2023-08-07
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
646
Registration Number
NCT05980156
Locations
🇲🇼

Kamuzu University of Health Sciences, Blantyre, Malawi

Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania

Not Applicable
Completed
Conditions
Malaria
Chemoprophylaxis
Underfive Children
Interventions
First Posted Date
2023-05-25
Last Posted Date
2023-05-25
Lead Sponsor
Richard Mwaiswelo
Target Recruit Count
13800
Registration Number
NCT05874869
Locations
🇹🇿

Muhimbili University of Health and Allied Ssciences, Dar es Salaam, Tanzania

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

Phase 2
Completed
Conditions
Uncomplicated Plasmodium Falciparum
Interventions
First Posted Date
2023-04-25
Last Posted Date
2023-05-16
Lead Sponsor
Syamsudin Abdillah,Ph.D, Pharm D
Target Recruit Count
36
Registration Number
NCT05829187
Locations
🇮🇩

Kori Puskesmas, Tambolaka, East Nusa Tenggara, Indonesia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy